<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880395</url>
  </required_header>
  <id_info>
    <org_study_id>FH 57</org_study_id>
    <nct_id>NCT04880395</nct_id>
  </id_info>
  <brief_title>Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3</brief_title>
  <acronym>DOLCE</acronym>
  <official_title>Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Huésped</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal University of Bahia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Huésped</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol Title: DOLCE: Dolutegravir-Lamivudine for naïve HIV-Infected Patients with ≤200&#xD;
      CD4/mm3&#xD;
&#xD;
      Protocol Number: FH-57&#xD;
&#xD;
      Study Objectives: To assess the antiviral activity at week 48 of DTG+3TC among naïve HIV&#xD;
      patients with a CD4 count ≤200 cells /mm3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint: Proportion of patients with viral load &lt; 50 copies/mL at week 48 using the&#xD;
      ITT-exposed analysis (FDA snapshot) for the intent-to-treat exposed (ITT-E) population.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the antiviral activity of DTG+3TC and DTG+TDF/XTC at week 24&#xD;
&#xD;
        -  To evaluate the safety and tolerability of DTG+3TC and DTG+TDF/XTC over time&#xD;
&#xD;
        -  To assess the antiviral activity of DTG+3TC and DTG+TDF/XTC at week 48 in patients with&#xD;
           baseline viral load &gt;100,000 c/mL&#xD;
&#xD;
        -  To evaluate immunological activity (CD4+ lymphocyte [CD4 counts]) at Week 24 and Week 48&#xD;
&#xD;
        -  To assess the development of HIV-1 resistance in patients with virologic failure or&#xD;
           viral rebound treated with DTG+3TC or DTG+TDF/XTC&#xD;
&#xD;
        -  To evaluate the incidence of disease progression (HIV-associated conditions, AIDS and&#xD;
           death) of DTG + 3TC and DTG + TDF/XTC over time.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Proportion of patients treated with DTG+3TC and DTG+TDF/XTC with HIV-1 levels of less&#xD;
           than 50 copies/mL at week 24&#xD;
&#xD;
        -  Frequency, type and severity of adverse events and laboratory abnormalities and&#xD;
           proportion of patients who discontinue DTG+3TC or DTG+TDF/XTC due to adverse events or&#xD;
           death&#xD;
&#xD;
        -  Proportion of patients with baseline HIV-1 RNA &gt;100,000 c/mL that achieve virological&#xD;
           suppression at week 48 weeks,&#xD;
&#xD;
        -  Changes in CD4 count, CD8 count and CD4/CD8 ratio between baseline and 48 weeks&#xD;
&#xD;
        -  Number and type of resistance mutations in case of virologic failure (defined as a&#xD;
           confirmed viral above 200 copies/mL after week 24 copies/mL or viral rebound at any&#xD;
           timepoint)&#xD;
&#xD;
        -  Incidence of IRIS and disease progression (HIV associated conditions, AIDS and death).&#xD;
&#xD;
      Tertiary objectives:&#xD;
&#xD;
      ● TDF/XTCTo explore change in health-related quality-of-life for subjects treated with DTG&#xD;
      plus 3TC and DTG + TDF/XTC&#xD;
&#xD;
      Tertiary endpoints:&#xD;
&#xD;
      ● Change from Baseline in health-related quality of life using EQ-5D-5L and PHQ9 at Weeks 24,&#xD;
      and 48&#xD;
&#xD;
      Patient Population:&#xD;
&#xD;
      HIV-1-infected subjects aged &gt;18 years who are naïve to antiretroviral therapy with ≤200 CD4&#xD;
      cell/mm3&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Prospective, Phase IV, randomized, multicenter, parallel group study design&#xD;
&#xD;
      Regimens:&#xD;
&#xD;
      Dolutegravir 50 mg /lamivudine 300 mg QD FDC. Dolutegravir 50 mg QD plus tenofovir 300&#xD;
      mg/emtricitabine 200mg or plus tenofovir 300 mg/ lamivudine 300 mg.&#xD;
&#xD;
      Duration: 48 weeks&#xD;
&#xD;
      Sample size:230 subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">November 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the antiviral activity at week 48 of DTG+3TC among ART-naïve HIV patients with a CD4 count ≤200 cells/mm3.</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of patients with viral load &lt; 50 copies/mL at week 48 using the ITT-exposed analysis (FDA snapshot) for the intent-to-treat exposed (ITT-E) population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the antiviral activity of DTG+3TC and DTG+TDF/XTC (TDF/FTC or TDF/3TC) at week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Proportion of patients treated with DTG+3TC and DTG+TDF/XTC with HIV-1 levels of less than 50 copies/mL at week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of DTG+3TC and DTG+TDF/XTC over time</measure>
    <time_frame>week 24 and week 48</time_frame>
    <description>Proportion of patients who discontinue treatment due to adverse events or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the antiviral activity of DTG+3TC and DTG+TDF/XTC at week 48 in patients with baseline viral load &gt;100,000 c/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of patients with baseline viral load &gt;100,000 c/mL that reach HIV-1 levels of less than 50 copies/mL at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate changes in lymphocytes subsets between baseline and 48 weeks</measure>
    <time_frame>Week 24 and Week 48</time_frame>
    <description>Changes in lymphocytes subsets counts (CD4, CD8, CD4/CD8 ratio) between baseline and 24 and 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the development of HIV-1 resistance in patients with virologic failure or viral rebound whilst being treated with DTG+3TC or DTG+TDF/XTC</measure>
    <time_frame>week 24 and week 48</time_frame>
    <description>Number and type of resistance mutations in case of virologic failure (defined as a confirmed viral above 200 copies/mL on or after week 24 or confirmed viral rebound at any timepoint)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of disease progression (HIV-associated conditions, AIDS and death) with DTG+3TC and DTG + TDF/XTC treatment over time</measure>
    <time_frame>week 24 and week 48</time_frame>
    <description>Incidence of IRIS or disease progression (HIV associated conditions, AIDS and death).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Experimental : Dolutegravir plus Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DOVATO: Dolutegravir 50mg/lamivudine 300 mg, FDC, 1 coformulated tablet QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active comparator : TDF/XTC plus Dolutegravir (XTC stands for lamivudine OR emtricitabine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unit Dose:&#xD;
TDF/FTC 300/200 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD OR&#xD;
TDF/3TC 300/300 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention Arm: dolutegravir/lamivudine</intervention_name>
    <description>1 pill QD</description>
    <arm_group_label>Experimental : Dolutegravir plus Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)</intervention_name>
    <description>1 pill of each QD</description>
    <arm_group_label>active comparator : TDF/XTC plus Dolutegravir (XTC stands for lamivudine OR emtricitabine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has voluntarily signed and dated an informed consent form, approved by an&#xD;
             Institutional Review Board (IRB) / Independent Ethics Committee (IEC), after the&#xD;
             nature of the study has been explained and the subject has had the opportunity to ask&#xD;
             questions.&#xD;
&#xD;
          2. Documented HIV-1 infection defined as a positive rapid test or ELISA plus a plasma&#xD;
             HIV-1 RNA (&gt;1,000 copies/mL) or a positive western blot. A previous result performed&#xD;
             on the last 30 days can be used.&#xD;
&#xD;
          3. ≥18 years of age&#xD;
&#xD;
          4. Naïve to ARV therapies (defined as ≤ 10 days of prior therapy with any antiretroviral&#xD;
             therapy following an HIV diagnosis). Previous use of PrEP or PEP is allowed if there&#xD;
             is documented HIV seronegativity between the last prophylactic dose and the date of&#xD;
             HIV diagnosis.&#xD;
&#xD;
          5. HIV RNA at screening visit &gt; or = 1,000 copies/mL. A previous result performed on the&#xD;
             last 30 days can be used.&#xD;
&#xD;
          6. CD4 at screening &lt; or = 200 cells/mL A previous result performed on the last 30 days&#xD;
             can be used.&#xD;
&#xD;
          7. Subjects can comply with protocol requirements.&#xD;
&#xD;
          8. Subject agrees not to take any medication during the study, including over-the-counter&#xD;
             medicines or herbal preparations, without the approval of the trial physician.&#xD;
&#xD;
          9. Subject's general medical condition, in the investigator's opinion, does not interfere&#xD;
             with assessments and completion of the study.&#xD;
&#xD;
         10. A female may be eligible to enter and participate in the study if she is not pregnant&#xD;
             (as confirmed by serum pregnancy test negative at screening, and a urine negative test&#xD;
             at baseline), not lactating and at least one of the following condition applies:&#xD;
&#xD;
               1. Women with non-reproductive potential, defined as pre-menospausal females with&#xD;
                  documented tubal ligation or hysterectomy, or bilateral oophorectomy; or as&#xD;
                  post-menospausal women defined as 12 months of spontaneous amenorrhea, and ≥45&#xD;
                  years of age in women without hormonal replacement therapy.&#xD;
&#xD;
               2. Women with reproductive potential and agrees to follow one of the contraceptive&#xD;
                  options listed in the Appendix 3 from at least 15 days prior to the first dose of&#xD;
                  medication and until at least 30 days after the last dose of study medication and&#xD;
                  completion of the follow-up visit.&#xD;
&#xD;
        Any contraception method must be used consistently, in accordance with the approved product&#xD;
        label. All subjects participating in the study should be counselled on safer sexual&#xD;
        practices including the use of effective barrier methods and the choice of effective&#xD;
        contraceptive method should be documented in the eCRF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or breastfeeding, or women who plan to become pregnant in the&#xD;
             next year&#xD;
&#xD;
          2. Subjects testing positive for Hepatitis B surface antigen (+HBsAg) at screening, or&#xD;
             anticipated need for Hepatitis C virus (HCV) therapy with drugs with potential&#xD;
             drug-drug interaction during the study&#xD;
&#xD;
          3. Subjects with severe hepatic impairment (Child-Pugh class C), or unstable liver&#xD;
             disease (ascites, encephalopathy, coagulopathy, or oesophageal or gastric varices) or&#xD;
             cirrhosis.&#xD;
&#xD;
          4. Opportunistic infections that impede to start ART immediately (specifically&#xD;
             tuberculosis within the first 2 weeks of anti-tuberculosis treatment, and meningeal&#xD;
             tuberculosis or cryptococcosis within the first month of specific treatment. Subjects&#xD;
             with other suspected or confirmed active opportunistic infections and subjects with&#xD;
             tuberculosis or cryptococcal disease after the initial period can be included if&#xD;
             she/he can follow the protocol and if her/his participation could benefit the subject.&#xD;
             A clear documentation of these aspects must to be done in the clinical chart of the&#xD;
             participant.&#xD;
&#xD;
          5. Subjects who in the investigator's judgment, pose a significant suicidality risk.&#xD;
&#xD;
          6. History or presence of allergy to the study drugs or their components or drugs of&#xD;
             their class&#xD;
&#xD;
          7. Treatment with any of the following agents within 28 days of screening: radiation&#xD;
             therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune&#xD;
             responses; or treatment with an HIV-1 immunotherapeutic vaccine within 90 days of&#xD;
             screening; or exposure to an experimental drug or experimental vaccine within either&#xD;
             28 days, 5 half-lives of the test agent, or twice the duration of the biological&#xD;
             effect of the test agent, whichever is longer, prior to the first dose of&#xD;
             investigational product&#xD;
&#xD;
          8. Any previous evidence of resistance to dolutegravir (defined as the presence of G118R,&#xD;
             Q148 H/K/R or R263K), to lamivudine (presence of the mutation M184V) or resistance to&#xD;
             tenofovir (mutation K65R or more than 3 TAMs) with a Sanger sequence method or using&#xD;
             next-generation sequencing (NGS) at a frequency &gt;15%. If the subject does not have a&#xD;
             previous resistance test, the investigator can take the samples and randomize the&#xD;
             subject while awaiting the results (see section 4.8 for follow up).&#xD;
&#xD;
          9. Any verified Grade 4 abnormality.&#xD;
&#xD;
         10. Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal (ULN), or ALT ≥&#xD;
             3xULN and bilirubin ≥ 1.5xULN (with &gt;35% direct bilirubin)&#xD;
&#xD;
         11. Creatinine clearance of &lt;50mL/min via Cockroft-Gault method&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Ines Figueroa, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Huésped</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María Inés Figueroa, MD</last_name>
    <phone>541149817777</phone>
    <email>maria.figueroa@huesped.org.ar</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundación Huésped</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>1202</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Inés Figueroa, Md</last_name>
      <phone>(+54911) 49817777</phone>
      <email>maria.figueroa@huesped.org.ar</email>
    </contact>
    <investigator>
      <last_name>María Inés Figueroa, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. Cosme Argerich</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>C1155 AHD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diego Cecchini, Medico</last_name>
      <phone>1154976263</phone>
      <email>diegocec@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Damián Marota</last_name>
      <phone>11 6530-8538</phone>
      <email>damianpm@yahoo.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital de Infecciosas Francisco Javier Muñiz</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>1282</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis Francos, Md</last_name>
      <phone>(+54911) 4304 5555</phone>
      <phone_ext>228</phone_ext>
      <email>jl_franc@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Andrés Benchetrit, Md</last_name>
      <phone>(+54911) 67057596</phone>
      <email>benche2000@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>José Luis Francos, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto CAICI</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Parenti, Médico</last_name>
      <phone>+5493416199549</phone>
      <email>pfparenti@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dana Carbone</last_name>
      <phone>+54 9 3412 58-2512</phone>
      <email>danaacarbone@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Huésped</investigator_affiliation>
    <investigator_full_name>Maria Ines Figueroa</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>antiretroviral naive triple therapy. Dolutegravir-Lamivudine</keyword>
  <keyword>dual-therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD available upon request. The request should be supported with a hypothesis-driven project, that should include analysis plan</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>3 month after last patient last visit</ipd_time_frame>
    <ipd_access_criteria>By request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

